



• Name: Li-Tzong Chen

-Chair Professor, Kaohsiung Medical

University (KMU), Kaohsiung.

-Director, National Institute of Cancer

• Current Position & Affiliation: Research, National Institute of Cancer

Research, Tainan &

-President, Taiwan Oncology Society (TOS),

Taipei, Taiwan

• Country: Taiwan

## • Educational Background:

1975.08 - 1982.07 M.D. Kaohsiung Medical College, Kaohsiung, Taiwan

1992.08 –2001.07 Ph.D. Post-graduate School, Kaohsiung Medical University (KMU)

1984.08 - 1988.07 Residency and GI fellow training, Department of Medicine, Kaohsiung Medical University Hospital (KMUH)

1988.04 - 1990.03 Fellowship of Medical Oncology Training Program Institute of Biomedical Science (IBMS), Academia Sinica, Taipei

## • Professional Experience:

• Professional Organizations:

1988.08 - Physician staff, Division of Gastroenterology, Dep. of

Medicine, KMUH

1995.08 - Physician Staff, Division of Cancer Research, NHRI

2005.09 –2005.11 Visiting Scholar, Cancer Treatment Evaluation Program (CTEP), National Cancer Institute, National Institutes of Health, Bethesda,

**USA** 

2006.01 -2014.07 Investigator, National Institute of Cancer Research (NICR),

NHRI.


2014.08 - Distinguished Investigator and Director, NICR, NHRI

2018.08 - Chair Professor, Department of Internal Medicine, KMU, Kaohsiung

## • Main Scientific Publications:

- 1. Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS\*, Shan YS\*, Chen LT\*. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma -TCOG T1211 study. *Eur J Cancer* 2020 Jan;124:123-130.
- 2. <u>Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, Kim JS, Chen JS, Shim HJ, Rau KM, Choi HJ, Oh DY, Belanger B, **Chen LT\***. Liposomal irinotecan in</u>

www.ksmo.or.kr/ksmo2020



September 3 - 4, 2020 Seoul, Korea



- metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study. *Cancer Sci* 2020 Feb;111(2):513-527
- 3. Wang HC, Lin YL, Hsu CC, Chao YJ, Hou YC, Chiu TJ, Huang PH, Tang MJ\*, Chen LT\*, Shan YS\*. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. *Theranostics* 2019 Sep 23;9(24):7168-7183
- 4. <u>Kao TM, Liu YS, Shan YS, Ch'ang HJ, Chen LT\*.</u> Cure of un-resectable locally advanced pancreatic cancer after multidisciplinary therapy. *J Cancer Res Practice* 2018;5:27-31
- 5. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT\* for the NAPOLI-1 Study Group. Nanoliposomal irinotecan with 5-fluorouracil and leucovorin in metastatic pancreatic cancer after prior gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label phase 3 trial. *Lancet* 2016 Feb;387(10018):545-57.

www.ksmo.or.kr/ksmo2020